Endurant Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Endurant Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-33,191	Closed	-$2.99M	–	84
2021 Q4	$2.99M	Buy	+33,191	New	+$2.84M	0.72%	32
2021 Q3	–	Sell	-28,625	Closed	-$2.23M	–	62
2021 Q2	$2.23M	Buy	+28,625	New	+$2.17M	0.61%	44
2021 Q1	–	Sell	-28,378	Closed	-$4.84M	–	73
2020 Q4	$4.84M	Buy	+28,378	New	+$4.2M	1.74%	25
2020 Q1	–	Sell	-39,822	Closed	-$5.14M	–	66
2019 Q4	$5.14M	Buy	+39,822	New	+$4.02M	1.62%	21
2019 Q3	–	Sell	-3,753	Closed	-$570K	–	58
2019 Q2	$570K	Sell	3,753 -10,611	-74%	-$1.29M	0.22%	46
2019 Q1	$1.71M	Sell	14,364 -7,251	-34%	-$932K	0.68%	45
2018 Q4	$2.36M	Buy	21,615 +13,159	+156%	+$1.65M	1.25%	25
2018 Q3	$1.37M	Buy	8,456 +1,742	+26%	+$238K	0.61%	39
2018 Q2	$887K	Buy	+6,714	New	+$633K	0.38%	48
2018 Q1	–	Sell	-48,800	Closed	-$2.71M	–	82
2017 Q4	$2.71M	Sell	48,800 -18,500	-27%	-$980K	0.83%	44
2017 Q3	$3.05M	Buy	+67,300	New	+$2.69M	0.93%	38
2017 Q1	–	Sell	-8,400	Closed	-$230K	–	97
2016 Q4	$230K	Buy	+8,400	New	+$337K	0.1%	68

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Endurant Capital Management's SRPT Position: Q1 2022 in Review

Endurant Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 33,191 shares — an estimated $2.99M sold.

Endurant Capital Management first reported a position in SRPT in Q4 2016 and held it in 12 quarters. The position peaked at $5.14M in Q4 2019. 328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

Endurant Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
Endurant Capital Management sold 33,191 Sarepta Therapeutics shares in Q1 2022, an estimated $2.99M.
Endurant Capital Management first reported a position in Sarepta Therapeutics in Q4 2016 and held it in 12 quarters.
Endurant Capital Management's Sarepta Therapeutics position peaked at $5.14M in Q4 2019.
328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on Endurant Capital Management's 13F filing for Q1 2022, filed 16 May 2022.